


## **Prevalence of AF in the general population**


**Prevalence and age distribution in patients with atrial fibrillation** 




## **Electrophysiologic mechanisms of AF**


#### **Trigger** APC, post-extrasystolic pause, long-short cycle **Substrate Anatomical:** AR Atrial dilatation, ↑ deposition of collagen and ↑ fibrosis, Hypertrophy, Autonomic Loss of connecting protein Nervous **Electrophysiological:** Triangolo di Coumel Short ERP, System **ERP** dispersion, lack of ERP rate adaptation Vagal intraatrial conduction delay, Adrenergic functional conduction block.

# **Atrial Fibrillation In The Elderly**





## **Atrial Fibrillation: Pathological Changes With Age**



Congo red-stained paraffin sections from right atrial appendages showing atrial amyloid of different degrees as visualized by fluorescence microscopy. A- Minor amount of amyloid(0.5); B-major amount of amyloid (1.00). Original magnification 20.

Röcken et al; Circulation 2002; 106

Atrial Fibrillation In The Elderly Are older patients different?				
<b>Younger Patients</b>	<b>Elderly Patients</b>			
+/-	+++			
	der patients differer Younger Patients			

Associated to structural heart disease:

\*

- >Valvular heart disease (mitral)
- Coronary artery disease
- >Systemic hypertension
- >Hypertrophic cardiomyopathy
- >Dilated cardiomyopathy 🛛 😽
- Congenital cardiomyopathy (septum)
- Cardiomyopathy restrictive
- Cardiac tumors
- >Pericarditis
- >Cor pulmonale 🗦

## "Lone atrial fibrillation"


# **Atrial Fibrillation**

Not associated to structural heart disease: >Sinus node dysfunction >WPW syndrome >Brugada syndrome >Short QT syndrome

**Associated to other conditions:** 

- Hyperthyroidism
- Sleep apnoea syndrome
- Emery-Dreyfus dystrophy

# Sinus Node activity balance between intrinsic sinus function and extrinsic influence by ANS



Intrinsic sinus function (with block of autonomic influences)


118-(0.57 x età) +/- 18%

50 y = 89+/-16 bpm 60 y = 84+/-15 bpm 70 y = 78+/-14 bpm 80 y = 72+/-13 bpm


IHR is progressively reduced with age Adrenergic activity increases with age Sick Sinus Syndrome ECG manifestations

- Sinus Bradycardia spontaneus persistent, or intermittent, not secondary to drugs or vagal influence
- SA blocks and/or sinus pauses
- HR raise failure
- **Brady-tachy syndrome** (atrial arrhythmia alternating to sinus bradycardia or pauses)

# **Sick Sinus Syndrome** Different clinical ECG presentations (alone or together in the same patient)




Zipes. Cardiac Electrophysiology. 2000 W.B. Saunders Company



## **AF and the risk of STROKE**


In AF pts exists an ↑ risk of stroke or thromboembolic complications (5 times higher) and this association increases with age.

> Percentage of Strokes Associated with Atrial Fibrillation



Wolf PA et al, Arch Intern Med. 1987; 147: 1561-1564

## **Anticoagulation Paradox**



40 30 20 10 0 40-64 65-74 75+ Age group

Proportion of patients prescribed warfarin by age and risk group.

Burton et al J CV Risk 2001 858 pts; no contraindications

## **Atrial Fibrillation In The Elderly**

## Are older patients different?

	<b>Younger Patients</b>	<b>Elderly Patients</b>
<b>Associated Disease</b>	+/-	+++
Symptoms	+++	+
Paroxysmal/Permanent	Paroxysmal	Permanent
Thromboembolic Risk	+	+++
Hemorrhagic Risk	+/-	++

#### Antiarrhythmic theraphy is more difficult to manage

1- Altered liver and renal function
2- Electrolyte abnormalities
3- Poor compliance

Pathologic recovery time of sinus node (increased by ADDs therapy)

	i Martin	1 sec	
Do you		- Josef	
LA		~~~	-hr
	avr y		
Ang			
1 M	v2 1/~~~~/~~		-fr
	va v	_1	
	va strand		~
	v5 ,	$\sim$	
	ve »		

# **AF therapy in the Elderly:**

#### RHYTHM CONTROL STRATEGY

# RATE CONTROL THERAPY

Atrial fibrillation Rate control

Advantages


• Simpler than rhythm control (less hosp)

• Easily achieved in all pts (rarely some may need AV node ablation/PMP)

• Avoids proarrhythmic effects of antiarrhythmic drugs

## **AFFIRM: Total Mortality (at 5 years)**

#### Rate control vs Rhythm control Rate control therapy vs Rhythm control therapy



New Engl. J. Med 2002;347:1825–1833

# **Atrial fibrillation**

**Rhythm control**: Antiarrhythmic drugs/ECV

**Potential benefits** 

- Improved symptoms
- Improved CO/exercise tolerance
- Reduced embolic risk

**Disadvantages** 

- Proarrhythmic effect
- False sense of security  $\rightarrow$  OAC interruption



# **AFFIRM:**

## "On treatment" analysis in a subgroup of 2796 pts


## **Covariates associated to survival:**

Covariate	р	HR	
Sinus Rhythm Warfarin	<0.0001 <0.0001	0.53 0.50	RS e Warfarin ↓of about 50% risk of death
Antiarrhythmic drugs Digoxin	5 0.0005 0.0007	1.49 1.42	AADs and digoxin ↑ of about 50% risk of death

Circulation 2004; 109:1509

Sinus Rhythm is better but antiarrhythmic therapy is difficult to manage


# ...so Catheter Ablation may be a useful therapeutic option



# **Efficacy and Safety in Middle age Patients**


## Long-term efficacy of AF Ablation (mean FU 3.5 y) Total population: 2225 pts, mean age 59 y

• Multiple Procedure (mean success 75%)



# **Symptomatic Complications in AF ablation**

Tamponade 0.3-1.3% Stroke/TIA 0.5-0.9%		
Complications	Pts	1.6%
Deaths	0	0
Stroke	1	0.1
TIA	4	0.4
Severe PV stenosis	3	0.3
Tamponade/Perf	5	0.5
Vascular complic	3	0.3
	Verma Circu	ilation 2005




# **Efficacy and Safety in the Elderly?**

# Long-Term Clinical Efficacy and Risk of Catheter Ablation for AF in the Elderly

32/1165 pts (2.7%) ≥ 75 y, 60% Paroxysmal AF PVI or ablation of other AF triggers






#### Long-Term Clinical Efficacy and Risk of Catheter Ablation for AF in Octogenarians

#### Adverse Events at 1 year after RF ablation for AF

Characteristic	<80 Years (N = 717)	≥80 Years (N = 35)	P-Value
Death	0.7 (5)	0.0 (0)	0.99
Myocardial infarction Cerebrovascular event	0 (0)	0 (0)	-
Stroke	0.6 (4)	0 (0)	0.99
Transient ischemic attack	0.3 (2)	0 (0)	0.99
Perforation with tamponade	1.3 (9)	2.8 (1)	0.08
Pulmonary vein stenosis	0.1 (1)	0 (0)	-
Deep venous thrombosis	0 (0)	2.8 (1)	0.05
Esophageal injury	0 (0)	0(0)	-
Vascular injury	0.1 (1)	0 (0)	1.00
Phrenic nerve injury	0 (0)	0 (0)	-
Urinary tract infection	1.0 (7)	2.9 (1)	0.32

#### Bunch T.J et al PACE 2010;33:146-152


**AF Ablation in the Elderly:** Results from retrospective and small studies Total population: **3935** pts; *age* > 70 years: **434** pts (11%)






1996-2001


Pts 247




Proc. Durat. 4 h.











Proc. Durat. 2 h. X-Ray:22'









Pts =250 Dur. Proced. 1.30 h. X-Ray:6'

2010





# 8.000.000 pts with AF all around the world

treated with ablation in the world 200.000 pts (2.5%)

Out of 200.000 pts, only 10% (20.000) are > 70 y

20.000/5.600.00 (0.4%) AF Elderly pts are treated with ablation

**5.600.000** are

> 70 years old

Atrial Fibrillation in the elderly Conclusions

Ablation is an effective and safety therapeutic option also in the Elderly

The limited use of AF ablation in elderly (0.4% in the total world population) is not supported by clinical data (inefficacy or increased complications), but is related to limited resources and current physician belief